Skip to content Skip to footer
Subscribe Now
NEWS

Leads Biolabs and Dianthus Therapeutics Sign ~$1B Licensing Deal to Jointly Advance LBL-047

Shots:Leads Biolabs has granted Dianthus exclusive global rights to develop, manufacture, & commercialize LBL-047 as DNTH212 outside of Greater ChinaAs per the deal, Dianthus will get $20M upfront, $5M in Q4’25, & ~$13M in near-term milestones, with a total potential value of ~$1B incl. development, regulatory, & commercial milestones, plus tiered royalties from…
October 17, 2025

Read more

NEWS

Hinge Bio Collaborates with Kyorin Pharmaceutical to Advance HB2198 in Japan for Autoimmune Diseases

Shots:Hinge Bio & Kyorin have entered into a collaboration & license agreement to develop HB2198 in Japan for various autoimmune diseases, starting with systemic lupus erythematosus (SLE), which is expected to enter trials by H2’25As per the deal, Hinge will lead global HB2198 development & receive $10M upfront, ~$95M in SLE milestones, plus additional…
October 1, 2025

Read more

NEWS

Enlaza Therapeutics Collaborates with Vertex to Develop Drug Conjugates and T-Cell Engagers for Improved Conditioning and Autoimmune Diseases

Shots:Enlaza & Vertex’s muti-target collaboration will leverage Enlaza’s War-Lock platform to develop small format drug conjugates & T-cell engagers for autoimmune diseases & improved conditioning in sickle cell disease & β thalassemiaEnlaza will receive $45M in upfront & equity investment & is eligible for >$2B in research, development, regulatory, & commercial milestones plus…
September 3, 2025

Read more

NEWS

Xcell Biosciences and ThermoFisher Enter Into a Joint Research Collaboration to Advance Cell Therapies

Shots:Xcell Biosciences entered into a strategic collaboration with ThermoFisher Scientific to advance the development of Treg and TIL cell therapies for autoimmune and solid tumor treatmentsThe joint research aims to develop methodologies for enhancing the efficacy of Tregs and TILs, while streamlining and scaling cell therapy manufacturing for improved accessibility and reproducibility across…
June 25, 2025

Read more

NEWS

Harbour BioMed Enters a ~$670M Partnership with Otsuka Pharmaceutical to Advance HBM7020 for Autoimmune Diseases

Shots:Harbour BioMed & Otsuka Pharmaceutical have entered into a global strategic collaboration to advance HBM7020 for the treatment of autoimmune diseasesAs per the deal, Otsuka will receive an exclusive global license to develop, manufacture, & commercialize HBM7020 excl. Mainland China, Hong Kong, Macau & Taiwan in exchange for $47M in upfront & near-term…
June 23, 2025

Read more

Cullinan and Genrix Bio
NEWS

Cullinan Therapeutics Enters a ~$712M Licensing Deal with Genrix Bio for Velinotamig

Shots:Genrix Bio has granted Cullinan exclusive global license to velinotamig, excl. Greater China for all indications, with Cullinan planning to develop it in autoimmune diseasesAs per the deal, Genrix will receive $20M upfront, ~$292M in development & regulatory milestones & ~$400M in sales-based milestones, with net sales-based tiered royalties from mid-single digits up to…
June 5, 2025

Read more

Sanofi
NEWS

Sanofi Enters a ~$1.84B Global License Agreement with Earendil Labs for HXN-1002 & HXN-1003

Shots:Earendil Labs has granted Sanofi exclusive global rights to develop HXN-1002 & HXN-1003 bispecific antibodies for autoimmune & inflammatory bowel diseasesAs per the deal, Earendil Labs will receive $125M upfront, ~$1.72B in development & commercial milestones, incl. a near-term $50M payment, & tiered royalties ranging from high-single to low-double digitsDeveloped using Earendil…
April 17, 2025

Read more

Viewpoints_Fred Aslan
VIEWPOINTS

Enhancing Care with NK Cell Therapy: Fred Aslan from Artiva Biotherapeutics in Conversation with PharmaShots

Shots: Immune reset in oncology has been observed with approved autologous CAR-T products. A recent study published in Nature demonstrated B-cell reconstitution and immune reset in systemic lupus erythematosus (SLE) patients treated with a CD19 autologous CAR-T, showcasing promising potential in autoimmune diseases Today, at PharmaShots, we have Fred Aslan shedding light on Artiva's AlloNK,…
November 4, 2024

Read more

Load more